Idera Pharmaceuticals to Present at the Nucleic Acid Summit 2014
June 13 2014 - 4:25PM
Business Wire
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage
biopharmaceutical company developing novel nucleic acid
therapeutics for orphan diseases, today announced that Walter
Strapps, Ph.D., Executive Director of RNA Therapeutics, will
present at the Nucleic Acid Summit 2014 in San Diego, California on
Thursday, June 19, 2014 at 4:15 p.m. PDT. The title of Dr. Strapps’
presentation is "Gene Silencing Oligos: The Next Generation in Gene
Silencing."
A copy of the presentation will be available on the Idera
website located at:
http://www.iderapharma.com/our-science/key-presentations-and-publications.
About Idera Pharmaceuticals, Inc.Idera Pharmaceuticals is
a clinical-stage biopharmaceutical company developing a novel
therapeutic approach for the treatment of genetically defined forms
of B-cell lymphoma and orphan autoimmune diseases. Idera’s
proprietary technology involves creating novel nucleic acid
therapeutics designed to inhibit over-activation of Toll-like
Receptors (TLRs). In addition to its TLR programs, Idera is
developing gene silencing oligonucleotides (GSOs) that it has
created using its proprietary technology to inhibit the production
of disease-associated proteins by targeting RNA.
Idera Pharmaceuticals, Inc.Sarah Carmody,
617-679-5552scarmody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024